RWE/RWD

 

 

Here we will focus on data curation and collection to drive forward new cures. Transferring Real World Data to Real World Evidence and the development of new cures. Curating data at scale is fraught with challenges on how to best go about this. We will explore how new partnership models are driving forward data porosity across the health system as a whole from payers, pharma, hospitals, regulators and central databanks. Learn about new integrated methods and what the future holds for this space.

THIS YEAR’S WORLD LEADING RWE/RWD SPEAKERS

 

 

 

RWE & RWD, Tuesday 2 November 2021

10:40

Networking Break

Bernard Hamelin
RWE & RWD
11:40

The RWD & Advanced Analytics Revolution – The Transformation of Pharmaceuticals to Reduce Risk, Accelerate R&D & Develop Pipelines of The Future

James Stover
RWE & RWD
12:00

Opportunities for leveraging genotype/phenotype data for translational research

Parker Moss
RWE & RWD
12:20

Genomics in Drug Development – Whole Genome Sequencing and Beyond

  • Genomics England and national scale whole genome sequencing
  • Target discovery and RWE and cancer research
  • Diagnostic discovery and the future of rare disease
Joanne Hackett
RWE & RWD
12:40

RWE provides unique value across the product lifecycle

  • As medicine moves towards genetically informed clinical management, RWE will be expected to provide genetically-stratified evidence
  • Clinical trials success may depend on matching treatment to genetic profile of patients; and
  • There is a growing number of targeted therapies, therefore biomarkers are of increasing importance to provide reliable patient stratification in RWE studies
Lana Denysyk
RWE & RWD
13:00

Building a RWD ecosystem to generate RWE

13:20

Networking Lunch Break

Maria Del Pilar Schneider
RWE & RWD
15:00

What are the challenges associated to RWD/RWE in rare diseases?

  • How to assess whether RWD can support your business or medical questions?
  • Will RWD provide you the level of granularity you need?
  • What type of data we would like to have in the future?
Maria Escala-Garcia
RWE & RWD
15:20

Where OMOP/ OHDSI fits in the Biomedical data landscape. Limits and possibilities for integration with genomics and other data types

Mary Helen Black
RWE & RWD
15:40

Leveraging large-scale population-based data to inform drug efficacy and safety studies

Christophe Maes
RWE & RWD
16:00

IDHIS - Building, leveraging & driving trust in RWE/RWD platforms

16:20

Networking Break

RWE & RWD
17:00

Sponsorship Available

18:00

Neri & Sons Band & Networking Drinks Reception

last published: 25/Oct/21 15:50

RWE & RWD, Wednesday 3 November 2021

10:20

Networking Break + Speed Networking

Adrian Jonas
RWE & RWD
11:20

The other side of the tunnel: What a primary role change from NICE to NHSE&I has taught me about leading the creation of RWE ecosystems and how integrated care systems might how the key in the UK

Sanjoy Paul
RWE & RWD
11:40

Opportunities in Identifying High Risk Population for Early Diagnosis & Better Outcomes in Cancer Patients

Alexander Sherman
RWE & RWD
12:00

How the lines between health system and pharma should be redrawn to allow patient data flow

Adrian Egli
RWE & RWD
12:40

Sepsis and Data Sharing: Developing an Architecture for AI Driven Digital Biomarker Development

13:00

Networking Lunch Break

Elise Bordet
RWE & RWD
14:40

Utilization of Real-World Evidence for Drug Development in Oncology

  • External control arm for oncology development
  • Modelling and prediction of non-adherence in breast cancer
  • Prediction of the best indication for a drug in oncology
16:00

Networking Break

18:00

Drinks Reception

last published: 25/Oct/21 15:50

RWE & RWD, Thursday 4 November 2021

last published: 25/Oct/21 15:50

 

GET INVOLVED AT BIODATA WORLD CONGRESS

 

 

TO SPONSOR


Alistair Wilmot
alistair.wilmot@terrapinn.com
0207 092 1174

 

 

TO SPEAK


Edward Glanville

edward.glanville@terrapinn.com
0207 092 1042

 

 

MARKETING OPPORTUNITIES


Onika Akhtar
onika.akhtar@terrapinn.com
0207 092 1034